AAAnkit Agarwal

Ankit Agarwal

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ankit Agarwal has a total of 43 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Prevalence and predictors of coeliac disease in patients with irritable bowel syndrome: A prospective study from Rajasthan, India

    by Dholavan Mayur, Ankit Agarwal, Chhagan Lal Birda, Vivek Chowdary Gogineni, Terence Susngi, Mahendra Kumar Garg, Bharat Kumar, Ashish Agarwal

    Our study aims to assess the prevalence of coeliac disease (CD) among patients with irritable bowel syndrome (IBS), a recognised high-risk group for CD, in Rajasthan. We found 9/287 consecutive adult IBS patients seropositive or with biopsy-confirmed CD. Lower haemoglobin levels were independently associated with CD.

  • Global Prevalence of Adherence to Gluten-Free Diet in Patients With Celiac Disease: A Systematic Review and Meta-Analysis

    by Shubham Mehta, Ashish Chauhan, Dwarakanathan Vignesh, Ritik Mahaveer Goyal, Raghavendra Puri, Vishwesh Bharadiya, Suyasha Gupta, Pavit Singh, Ankit Agarwal, Aditya Vikram Pachisia, et al.

    INTRODUCTION: Strict and life-long gluten-free diet (GFD) is the standard of care for patients with celiac disease (CeD). Maintenance of adherence to GFD is the key to the success of GFD; however, a proportion of patients are unable to maintain strict adherence to GFD. METHODS: We performed a systematic review and meta-analysis to estimate the pooled prevalence of adherence of GFD, as assessed by celiac dietary adherence test, BIAGI score, standardized dietitian evaluation or self-reported adherence to GFD, in patients with CeD after at least 1 year of initiating GFD. Electronic reference databases were searched from January 1, 1990 to April 30, 2025. Overall, 69 studies including 27,641 subjects were found eligible for pooling estimates by objective assessment methods. The pooled effect size (95% confidence interval [CI]) was calculated using a random effect model. RESULTS: Most of the studies had low risk of bias and there was no publication bias. The pooled prevalence of adherence to GFD as assessed by objective methods of assessment and self-reported adherence were 64% (95% CI 59%–69%) and 74% (95% CI 69%–79%), respectively. Specifically adherence rates were 65% (95% CI 57%–73%) with standardized dietitian evaluation, 57% (95% CI 50%–64%) with celiac dietary adherence test and 75% (95% CI 65%–83%) with BIAGI score. Highest adherence rates were reported from European and North American countries. There was no significant difference in the adherence rates with time or age of the participants. On univariate metaregression, method of assessment of adherence affected the rate of adherence to GFD. DISCUSSION: One in 3 patients with CeD is unable to maintain a good adherence to GFD. There is need to develop strategies to improve the adherence to GFD.


  • Celiac Disease and Its Impact on Liver‐Related Outcomes in Patients With All‐Cause Cirrhosis: The CELIHEP Study

    by Ankit Agarwal, Aditya Vikram Pachisia, Samagra Agarwal, Shubham Mehta, Alka Kumari, Anam Ahmed, Sonu Sharma, Sambuddha Kumar, Lalita Mehra, Prasenjit Das, et al.

    Background and Aims: Celiac disease (CeD) is a multisystem disease and may coexist in patients with cirrhosis. We aimed to assess (1) CeD prevalence in all‐cause cirrhosis, (2) the impact of a gluten‐free diet (GFD) on liver‐related outcomes in definite CeD, and (3) characteristics and follow‐up of patients with positive celiac serology and cirrhosis without enteropathy. Methods: A total of 1959 consecutive patients with cirrhosis were screened for CeD using IgA anti‐tissue transglutaminase antibody. All those having elevated anti‐tTG Ab underwent anti‐endomysial Ab testing and duodenal biopsies. Patients with definite CeD matched with those without CeD (1:4; CeD: no CeD matched for age, sex, baseline CTP, and MELD) were initiated on GFD plus standard of care (SOC) and SOC and followed up for 1 year. Results: Definite CeD was identified in 35 of 1959 (1.8%; 95% CI: 1.2%–2.4%) ( n = 35; mean age: 37.3 ± 12.3; Child–Pugh Stage A/B/C: 17.1%/57.1%/25.7%; median MELD 19 [IQR: 17–22]), whereas the prevalence of positive celiac serology without enteropathy was 140 of 1959 (7.2%; 95% CI: 6.0%–8.3%). New‐onset liver decompensations (34.3% vs. 44.3%) and mortality (17.1% vs. 13.6%) were similar in patients with CeD on GFD ( n = 35) and the matched ( n = 140) cohort without CeD over 1 year, but liver stiffness measurement decreased significantly in patients with CeD (28.5 ± 14.3 vs. 41.2 ± 18.31; p = 0.001). Patients with definite CeD showed normalization of celiac serology on GFD. One‐year follow‐up IgA tTG normalized in 88 of 122 (72.1%) patients with positive celiac serology without enteropathy without GFD. Conclusion: Patients with cirrhosis of the liver, irrespective of underlying etiology, should be screened for CeD. Early diagnosis of CeD and GFD may improve prognosis and clinical outcomes in patients with cirrhosis of the liver.


  • Celiac Disease Is Common in Adults With Cryptogenic Cirrhosis and Responds Favorably to Gluten-Free Diet

    by Aditya Vikram Pachisia, Ankit Agarwal, Shubham Mehta, Alka Kumari, Vignesh Dwarakanathan, Sonu Sharma, Sambuddha Kumar, Lalita Mehra, Rimlee Dutta, Prasenjit Das, et al.

    INTRODUCTION: Liver involvement is common in celiac disease (CeD), and up to 4.6% of patients with cryptogenic cirrhosis have CeD. We investigated the prevalence of CeD in patients with cryptogenic cirrhosis and assessed liver-related outcomes in them on GFD when compared with a propensity score–matched cohort of patients with cryptogenic cirrhosis without CeD. METHODS: Consecutive patients with cryptogenic cirrhosis were screened for CeD using IgA anti–tissue transglutaminase antibody (anti-tTG) followed by antiendomysial antibody and duodenal and liver biopsies, on which IgA/anti-tTG colocalization studies were performed. These patients and a cohort of patients with cryptogenic cirrhosis without CeD (1:4 CeD: no CeD matched using propensity score matched for age, sex, Child–Turcotte–Pugh [CTP] and model for end-stage liver disease [MELD]) were initiated on GFD plus standard of care and standard of care, respectively, and followed up for liver-related outcomes for 1 year. RESULTS: Of 232 patients with cryptogenic cirrhosis, 14 had high anti-tTG Ab (16.9 ± 10.5 fold rise), with 9 antiendomysial antibody–positive and 11 (4.7%) biopsy-proven CeD. IgA/anti-tTG Ab colocalization was demonstrated in 7/8 liver and 10/11 duodenal biopsies. Patients with cryptogenic cirrhosis with definite CeD (n = 11) and matched cohort without CeD (n = 44) were similar at baseline (age: 31.3 ± 7.7 vs 31.8 ± 9.3 years; 5 [45.5%] vs 15 [34.1%] females; MELDNa 9 [interquartile-range: 8–15.5] vs 12 [9–15]; CTP 7 [6–7.5] vs 6 [5.75–7]). Patients with CeD on GFD improved significantly on follow-up compared with those without CeD (follow-up MELDNa: 9 [7.5–10.5] vs 18.5 [12-20]; P = 0.001 and follow-up CTP: 5 [5-5] vs 8 [7–9]; P < 0.001) with less frequent further decompensations and similar mortality (9.1% vs 18.2%; P = 0.67). DISCUSSION: Approximately 4.7% of patients with cryptogenic cirrhosis have biopsy-proven CeD, and their liver-related outcomes improve with GFD.


  • Open Access

    Efficacy of a Reduced-dose Rasburicase: Single-institution Experience in India

    by K C Lakshmaiah, K Govind Babu, L K Rajeev, D Loknatha, Linu Jacob Abraham, M C Suresh Babu, K N Lokesh, A H Rudresha, Ankit Agarwal

    Background: Tumor lysis syndrome (TLS) is an oncological emergency associated with life-threatening metabolic abnormalities. Hyperuricemia is a feature of TLS and is treated with hydration, urine alkalinization, and allopurinol. Rasburicase lowers uric acid (UA) rapidly at the labeled dose of 0.15–0.2 mg/kg/day for 5 days. In a developing country like India where affordability is one major limitation to medical care, the use of rasburicase at the dose recommended by the US Food and Drug Administration (FDA) is not always possible. There is no convincing data suggesting the efficacy of a lower dose of rasburicase (1.5 mg or 3 mg) in the treatment of TLS. We conducted a retrospective study from January 2015 to June 2016 to assess the efficacy of a reduced-dose rasburicase in patients with TLS. Materials and Methods: All the patients with TLS were given rasburicase (single dose of 1.5 mg) on day 1 of chemotherapy. Serum UA, potassium, creatinine, and calcium levels were monitored every 24 h. All the patients who did not achieve normalization of UA with one dose of rasburicase were given another 1.5 mg of rasburicase. Results: Out of 90 patients, 54 patients (60%) had normalization of UA levels after 1.5 mg of rasburicase and 16 (18%) patients required 3 mg of rasburicase for bringing down the UA level to normal. The low serum UA levels were maintained even on the 3rd day of rasburicase. Rasburicase was well tolerated, and there was no death due to TLS. Thirty-one patients (64%) had normalization in the serum creatinine levels after rasburicase. Conclusion: We conclude that a low dose of rasburicase (1.5 mg or 3 mg) is cost effective in reducing serum UA (especially for low-risk and intermediate-risk TLS) and the higher dose as recommended by the US FDA is required only for patients with high-risk TLS.